-
Statins and diabetes risk; new treatment guideline for diabetes; new pertussis vaccine recommendation; antibiotics and rhinosinusitis; fluoroquinolones and cystitis; and FDA actions.
-
Preliminary trials of low-dose intranasal insulin suggest a possible benefit that warrants further investigation.
-
REM behavior disorder can be reliably diagnosed using a simple bed-partner questionnaire and its presence is a risk factor for a future neurodegenerative disease.
-
The clinicopathological features of nine patients with pure autonomic neuropathy, with or without antiganglionic acetylcholine antibody, were assessed. There was considerable variability in the clinical manifestations, course, unmyelinated nerve fiber loss, and response to therapy.
-
Isoflurane causes mitochondrial disruption and apoptosis in neuronal and hippocampal cells, and decreases memory consolidation in mice. Such effects are not seen with desflurane. This may impact selection of anesthetic agents for patients with Alzheimer's disease undergoing surgical procedures.
-
Based on a retrospective analysis of 77 patients with monophasic and recurrent inflammatory spinal cord disease, the authors report significantly lower vitamin D levels in patients with recurrent disease.
-
Drug shortages; metformin and cancer prevention; migraine prevention guidelines; and FDA actions.
-
-
Vorapaxar is a potent antiplatelet medication with a novel action that works by inhibiting thrombin activation of platelets through the protease-activated receptor PAR-1.
-
With the advent of specific genetic tests, atypical forms of facioscapulohumeral muscular dystrophy can be reliably diagnosed.